Aduro BioTech Inc (ADRO) Given Average Recommendation of “Hold” by Brokerages

Shares of Aduro BioTech Inc (NASDAQ:ADRO) have been assigned an average recommendation of “Hold” from the ten research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $13.80.

A number of brokerages have issued reports on ADRO. BidaskClub raised shares of Aduro BioTech from a “sell” rating to a “hold” rating in a research note on Saturday, September 29th. HC Wainwright set a $8.00 target price on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Tuesday, October 2nd. ValuEngine raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. William Blair reissued a “buy” rating on shares of Aduro BioTech in a research note on Wednesday, October 3rd. Finally, Canaccord Genuity reissued a “buy” rating and set a $30.00 target price on shares of Aduro BioTech in a research note on Thursday, August 2nd.

Shares of NASDAQ:ADRO opened at $4.66 on Friday. The firm has a market cap of $370.02 million, a price-to-earnings ratio of -3.28 and a beta of 2.70. Aduro BioTech has a 12-month low of $3.69 and a 12-month high of $10.00.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Tuesday, October 30th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. The company had revenue of $3.06 million during the quarter, compared to analyst estimates of $4.59 million. Aduro BioTech had a negative net margin of 591.66% and a negative return on equity of 50.03%. Equities research analysts expect that Aduro BioTech will post -1.18 earnings per share for the current fiscal year.

In related news, insider Stephen T. Isaacs sold 24,143 shares of Aduro BioTech stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total value of $156,929.50. Following the completion of the sale, the insider now owns 356,996 shares of the company’s stock, valued at approximately $2,320,474. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Stephen T. Isaacs sold 62,572 shares of Aduro BioTech stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $7.91, for a total transaction of $494,944.52. Following the completion of the sale, the insider now directly owns 221,331 shares of the company’s stock, valued at approximately $1,750,728.21. The disclosure for this sale can be found here. Insiders have sold a total of 113,160 shares of company stock valued at $819,523 in the last three months. Company insiders own 5.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in Aduro BioTech by 32.5% in the 2nd quarter. BlackRock Inc. now owns 4,706,526 shares of the biotechnology company’s stock worth $32,945,000 after acquiring an additional 1,153,301 shares during the period. FMR LLC raised its holdings in Aduro BioTech by 12.1% in the 2nd quarter. FMR LLC now owns 3,263,888 shares of the biotechnology company’s stock worth $22,847,000 after acquiring an additional 351,013 shares during the period. Baillie Gifford & Co. raised its holdings in Aduro BioTech by 69.6% in the 2nd quarter. Baillie Gifford & Co. now owns 2,810,508 shares of the biotechnology company’s stock worth $19,673,000 after acquiring an additional 1,153,771 shares during the period. Aquilo Capital Management LLC bought a new position in Aduro BioTech in the 2nd quarter worth $14,055,000. Finally, Citadel Advisors LLC raised its holdings in Aduro BioTech by 958.5% in the 2nd quarter. Citadel Advisors LLC now owns 1,590,832 shares of the biotechnology company’s stock worth $11,136,000 after acquiring an additional 1,440,546 shares during the period. 48.17% of the stock is owned by institutional investors and hedge funds.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

See Also: Intrinsic Value and Stock Selection

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply